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Introduction: Peripheral cytopenias are common in systemic lupus erythematosus (SLE), but bone marrow
involvement is rarely reported. Myelofibrosis is a rare disorder characterized by reticulin fibrosis of the bone marrow,
which usually occurs in response to clonal proliferation of hematopoietic stem cells in myeloproliferative disorders.
However, bone marrow fibrosis has also been described in association with auto-immune diseases, especially SLE.
Method: We will report here a new case of bone marrow fibrosis associated with SLE. We also reviewed the 27
cases published in the English language literature, and will discuss the clinical presentation, outcome, treatment,
and pathophysiology of bone marrow fibrosis occurring in association with SLE.
Results: Over one half of patients were diagnosed concomitantly with bone marrow fibrosis and SLE.
Epidemiological, clinical and biological features of lupus were unremarkable. Except for the presence of reticulin
fibrosis, the findings from the bone marrow biopsies proved highly variable. Overall mortality was about 14% but
corticosteroid-based therapy lead to clinical improvement and reverted bone marrow fibrosis in most cases. Data
on the usefulness of other immunomodulatory therapies are inconclusive.
Conclusions: SLE may be complicated by bone marrow involvement, of a likely autoimmune origin. Bone marrow
fibrosis occurring with SLE is probably similar to “primary autoimmune myelofibrosis” and may respond to steroid
and immunomodulatory therapies. Further studies with standardised proofreading of bone marrow aspirations and
biopsies are needed to delineate the clinical and biological features of this rare complication of SLE.
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Hematological abnormalities such as anemia, auto-immune
hemolysis, leukopenia, lymphopenia and thrombocytopenia
are very common in systemic lupus erythematosus (SLE)
(Beyan et al. 2007). Blood cytopenias are among the criteria
for SLE in the revised American College of Rheumatology
(ACR) (Hochberg 1997) guidelines and may occur as the
first symptom of the disease. Most of these manifestations
are caused by increased peripheral destruction of blood cells
associated with circulating auto-antibodies. Occasional case
reports and small series have documented bone marrow ab-
normalities in patients with SLE, such as myelofibrosis,* Correspondence: emilie.chalayer@chu-st-etienne.fr
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in any medium, provided the original work is paplastic anemia, pure red cell aplasia, and features suggestive
of myelodysplastic syndromes, suggesting that the bone
marrow may also be a target organ in the disease. Bone mar-
row fibrosis is defined by the deposition of reticulin fibres in
the bone marrow stroma. Fibrosis usually occurs in response
to the clonal proliferation of hematopoietic stem cells (Kuter
et al. 2007). Sporadic reports have suggested that bone mar-
row fibrosis may be part of the SLE disease spectrum, and
the relationship between disease control and pancytopenia
improvement provides indirect evidence for a causal rela-
tionship between SLE and bone marrow fibrosis. Auto-
immune myelofibrosis may respond to immunosuppressive
treatment with regression of the fibrosis and regeneration of
the normal marrow tissue (Pullarkat et al. 2003). However,
bone marrow involvement in SLE has not been thoroughly
studied and the etiological mechanisms of this rarean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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bone marrow fibrosis associated with SLE. In order to
improve the knowledge on this rare but serious com-
plication of SLE, we have also reviewed all previously
published cases.
Case report
A 17 year-old woman with a history of polyarthralgias
and photosentivity was referred to the hospital in 1999
for the evaluation of a Raynaud’s phenomenon. Clinical
examination revealed no anomaly. She presented with
neutropenia (leukocyte count 2.4 × 109/l with 1.1 × 109/l
neutrophil granulocytes and 0.74 × 109/l lymphocytes)
without anemia or thrombocytopenia. Antinuclear anti-
bodies were present (>1/1280 with a speckled fluorescence
pattern). Anti-DNA antibodies were absent. Anti-U1-RNP
and anti-SSA antibodies were positive. Three years later
(2002), she was admitted to the hospital because of atyp-
ical eating disorder and psychotic behaviour. No evidence
for neuropsychiatric lupus was found despite an extensive
work-up. The patient was diagnosed with schizophrenia
and treated with olanzapine. Nine years later (2011), she
was referred to the hospital for fatigue, fever and pancyto-
penia. With the exception of extreme paleness, clinical
examination was unremarkable. Her weight is normal. La-
boratory findings on admission showed the following
values: leukocyte count 0,48 × 109/l with 0.28 × 109/l
neutrophil granulocytes and 0.08 × 109/l lymphocytes,
hemoglobin 2.9 g/dl, platelet count 15 × 109/l and re-
ticulocyte count 3 × 109/l, low-normal level of folate,
normal levels of vitamin B12 and ferritin. Anti-SSA,
anti-RNP 70 and anti-U1-RNP antibodies were posi-
tive. The anti-DNA antibody titer was 76 UI/ml in
ELISA [normal range < 10]. Direct Coombs’ test was
negative. C3, C4, and CH50 were respectively 1.18 g/l [nor-
mal range: 0.79–1.52], 0.12 g/l [normal range: 0.2–0.51] and
120%. Abdominal ultrasonography showed limit homogen
splenomegaly (around 12 cm). Tear drop cells or leukoery-
throblastic blood smear were not noted. Two attempts to
aspirate bone marrow at different sites were unsuccessful
and yielded only dry taps. Bone marrow biopsy showed
hypercellular marrow (cellularity: 80%) with focal lympho-
cytic infiltration, dysmyelopoiesis, erythrophagocytosis and
grade 1–2 fibrosis. JAK-2, MPL W515L/K, and calreticulin
mutations were not screen. A diagnosis of SLE with bone
marrow involvement was retained. High dose methylpred-
nisolone (500 mg/d) was given for 3 days. Then hydroxy-
chloroquine and prednisone (1 mg/kg) were started, in
addition to supportive care with blood transfusion and anti-
biotics. However, the patient remained pancytopenic. Intra-
venous immune globulins (30 g/d) were given for 4 days
with remarkable improvement. Hemoglobin level after
2 months was 11.8 g/dl, platelet count was 175 × 109/l
and leucocyte count was 3.27 × 109/l with 2.32 × 109/lneutrophil granulocytes and 0.49 × 109/l lymphocytes.
Prednisone was continued for 17 months and gradually
tapered. The patient did not experience change in her
mental status during the course of steroid treatment.
She remains in good physical health and still takes
hydroxychloroquine and olanzapine.
Review of published cases
Method
An electronic search of the literature was performed via
MEDLINE by crossing the key words “systemic lupus er-
ythematosus” AND [“bone marrow fibrosis” OR “myelo-
fibrosis”]. We then examined additional references from
the retrieved articles. The study period ran from January
1975 through December 2013. Only papers written in
English were reviewed.
Results
Clinical presentation (Table 1)
Of the 27 cases retrieved from the English language
literature and our case, 3 were males and 25 females,
giving a ratio of 1:9. The age range was 12 to 70 years
with a mean of 36 years and a median of 29 years. Fif-
teen patients received a concomitant diagnosis of SLE
and bone marrow fibrosis, and 13 patients who had been
previously diagnosed with SLE subsequently developed
bone marrow fibrosis. In these 13 cases, the onset of
bone marrow fibrosis varied from 8 months to 13 years
after SLE diagnosis, with a mean of 5 years. Seven of
these patients were under corticosteroids at the time of
the hematological complication, two patients were under
hydroxychloroquine, one had discontinued azathioprine
at least 4 months before (Kiss et al. 2000) and one had
started azathioprine two weeks before, but 4 weeks after
discontinuing the drug no improvement had been ob-
served (Vora et al. 1998). In patients with previously di-
agnosed SLE, symptoms attributed to the disease before
bone marrow fibrosis occurred were rheumatologic symp-
toms (11/13), muco-cutaneous symptoms (8/13), renal in-
volvement (3/13), serositis (3/13), and seizures (1/13). For
all 28 patients, at the time of admission for cytopenias
subsequently attributed to bone marrow fibrosis, the phys-
ical findings suggestive of SLE were rheumatologic symp-
toms (8/28), renal involvement (7/28), serositis (6/28)
and muco-cutaneous symptoms (4/28). Splenomegaly
was found in 11/26 patients (2 patients had undergone
splenectomy due to immune thrombocytopenia), hep-
atomegaly in 11 patients, and lymph node enlargement
or small diffuse lymph nodes in 6 patients. The other
major symptoms reported were fever (17/28) and
bleeding (15/28). Previous hematological history was
often unclear, but at least 2 patients had been diag-
nosed with immune thrombocytopenia before the diag-
nosis of bone marrow fibrosis.
Table 1 Clinical presentation
Nref Age (yrs) M/F PD SLE SLE symptoms and signs Associed symptoms and signs LNE HMG SMG
1 (Sarkar et al. 2009) 45 M - Pleural effusion Fever, melena, epistaxis - - -
2 (Sacre et al. 2009) 44 F + Diffuse alopecia, arthritis -
3 (Pillai et al. 2009) 40 F - Proteinuria, pleural and pericardial
effusion, ascites
Fever - + -
4 (Aziz et al. 2004) 22 F - Membranous nephropathy Fever, epistaxis + + +
5 (Kiss et al. 2000) 18 F + Alopecia, facial erythema, arthritis Fever, weight loss, myositis - -
6 (Durupt et al. 2000) 29 F + Polyarthritis, mesangial
glomerulonephritis
Fever, hematuria - - -
7 (Vora et al. 1998) 22 F + Membranous nephropathy, seizures Severe recurrent posterior scleritis +
8 (Aharon et al. 1997;
Amital et al. 2003)
54 F - Arthralgias, pleural effusion Fever, weight loss, abdominal pain + + +
9 (Agarwal et al. 1995) 12 F + NS Fever, petechias - - -
10 (Ramakrishna et al.
1995)
18 F - Alopecia, arthralgias, Evans’ syndrome Fever, weight loss, menorrhagia,
headaches
- - -
11 (Paquette et al. 1994) 68 M - Pleural effusion, oral ulcers -
12 (Paquette et al. 1994) 27 F - NS Epistaxis, hematuria, gingival bleeding,
petechias
+ +
13 (Paquette et al. 1994) 23 F + Photosensitivity, alopecia, malar rash,
pharyngeal ulcerations, arthritis, oral
ulcers
Gingival bleeding, retinal lesion + +
14 (Paquette et al. 1994) 56 F + Alopecia, arthritis Cutaneous vasculitis -
15 (Paquette et al. 1994) 18 F - NS Fever, menorrhagia, epistaxis, gingival
bleeding, petechias
+ + +
16 (Paquette et al. 1994) 70 F - Arthritis, pleural effusion Fever, weight loss, hematemesis -
17 (Paquette et al. 1994) 62 F - Psychosis Fever, weight loss, panniculitis + +
18 (Paquette et al. 1994) 69 F + Arthritis, immune thrombocytopenia Petechias + S
19 (Hirose et al. 1993) 54 F + Oral ulcers, polyarthralgias Fever, weight loss




21 (Foley-Nolan et al.
1992)
20 F - Arthralgias -
22 (Inoue et al. 1992) 24 F - Proteinuria Fever, purpura - - -
23 (Matsouka et al. 1989) 60 F - Proteinuria, immune
thrombocytopenia
Fever, weight loss, petechias and
ecchymoses
+ S
24 (el Mouzan et al. 1988) 13 F - Arthritis Fever, anorexia, petechias and
ecchymoses
+ + +
25 (Kaelin and Spivak
1986)
27 F + Hyperpigmented skin rash,
polyarthralgias
Ecchymoses, epistaxis, melena, gingival
bleeding, purpura
- - -
26 (Nanji and Jetha 1984) 28 M + Erythematous macular lesions, arthritis,
deterioration in renal function, pleural
and pericardial effusion, ascites
Fever + +
27 (Daly and Scott 1983) 16 F - Alopecia, arthritis Weight loss, subcutaneous nodules in
hands, retinal exudates, epistaxis, gingival
bleeding, purpura and ecchymoses
+ + +
Present 29 F + Photosensitivity, polyarthralgias and
Raynaud’s phenomenon
Fever, edema - - +
PD: previous diagnosis of SLE, LNE: lymph node enlargement, HMG: hepatomegaly, SMG: splenomegaly, S: splenectomy, NS: not specified.
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Thirteen of the 28 patients had pancytopenia (anemia:
Hb <10 g/dl, leukopenia:WBC<4×109/l, and thrombocytopenia:platelets < 150 × 109/l), 13/28 had bicytopenia (anemia
or/and leukopenia or/and thrombocytopenia), 1/28 had
thrombocytopenia and neutropenia without leukopenia
Table 2 Biology
Nref Age yrs M/F Hb g/dl Pl 109/l WBC 109/l N 109/l L 109/l ANA DNA other Co test LC Bone marrow examination
1 (Sarkar et al. 2009) 45 M 5.3 25 2.5 1.2 1 1/640 + + Hypercellular marrow with focal lymphocytic infiltration.
2 (Sacre et al. 2009) 44 F 7 65 high + - Hypercellularity with marked reticulin fibrosis.
3 (Pillai et al. 2009) 40 F 10.6 25 0 1/320 - + + Hypercellular with increased megakaryocytes
and reticulin (grade 3).
4 (Aziz et al. 2004) 22 F 6.2 18 1.2 1/160 + Hypercellularity with an increased number of
megakaryocytes. Silver stain showed increased
reticulin fibrosis and the presence of patchy
areas of collagenized marrow.
5 (Kiss et al. 2000) 18 F 4.2 28 0.9 high aCL Significant increase in the amount of reticulin
fibres (40%, Beumaister 3–4), hypocellularity of
the myeloid components and massive
lymphocytic infiltration.
6 (Durupt et al. 2000) 29 F 9.4 102 1.1 0.6 0.3 1/1120 + + All normal hematopoietic elements with a small
increase in mature megakaryocytes and marked
inflammatory medullar reaction with plasmocytosis,
systematized increase in reticulin (grade 1).
7 (Vora et al. 1998) 22 F 9 60 4 1/1000 - Marked osteomyelosclerosis with severe fibrosis
of the marrow spaces and near-total effacement
of normal hematopoiesis.
8 (Aharon et al. 1997;
Amital et al. 2003)
54 F 5.1 96 3.1 2.2 0.6 high + aCL, anti-histone,
anti-SSA
+ Focal hypercellularity, many reticulin and collagen
fibers, normal appearance of the red cell and white
cell lines, mild megakaryocytosis with few mildly
abnormal megakaryocytes.
9 (Agarwal et al. 1995) 12 F 9.6 4 4.7 0.7 3.3 1/40 - - Extremely hypocellular marrow with
residual patches of hematopoietic cells. Reticulin
stain showed a marked increase in fine fibrosis,
which was diffuse grade 3.
10 (Ramakrishna et al. 1995) 18 F 5.4 30 6 1/2560 + LA, aCL,
antiplatelet
+ + Markedly hypercellular marrow with erythroid
hyperplasia, plentiful megakaryocytes and
markedly increased reticulin.
11 (Paquette et al. 1994) 68 M 5.7 222 3.5 1/5280 - + Hypercellular, increased stroma and reticulin
fibrosis.
12 (Paquette et al. 1994) 27 F 5 1 5.9 1/80 - + - Fibrosis with megakaryocyte clustering.
13 (Paquette et al. 1994) 23 F 9.5 55 4.2 high - Fibrosis, open sinusoids, megakaryocyte clusters.
14 (Paquette et al. 1994) 56 F 9.7 76 5.4 high + - + Erythroid hyperplasia, increased megakaryocytes,
fibroblast proliferation, reticulin fibrosis.
15 (Paquette et al. 1994) 18 F 2.7 4 7.7 high + + + Bone marrow fibrosis, hypercellular marrow,
increased megakaryocytes with clustering.
16 (Paquette et al. 1994) 70 F 4.2 20 3.8 high - + + Advanced bone marrow fibrosis, hypocellular
marrow, predominance of megakaryocytes.
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18 (Paquette et al. 1994) 69 F 6.8 39 6.8 high - - Hypercellular with increased, clustering
megakaryocytes; stroma moderately
increased by accumulation of fibrillar
reticulin.
19 (Hirose et al. 1993) 54 F 6.9 17 1.7 1/320 - aCL, LA + Marked marrow fibrosis with reduced numbers
of erythroid precursors and normal proliferation
of both megakaryocytes and myeloid series,
the reticulin content was increased.
20 (Borba et al. 1993) 39 F 9.7 341 2.4 0.9 1/200 - anti-neutrophil + + All normal hematopoeitic elements with
localised fibrosis, reticulin was moderately
increased.
21 (Foley-Nolan et al. 1992) 20 F 10.5 45 4.5 1.3 1.9 1/800 + + Hypercellular with a marked increase in the
number of megakaryocytes and a diffuse,
significant increase in reticulin content.
22 (Inoue et al. 1992) 24 F 6.8 2 3.8 1/100 - antiplatelet - + Bone marrow fibrosis characterized by marked
hyperplasic marrow with an increase in reticulin
fibers, all elements including megakaryocytes
increased in number.
23 (Matsouka et al. 1989) 60 F 20 4 1.4 1.4 1/320 - - Presence of dense fibrous tissue with fibroblasts,
paucity of immature and polymorphonuclear cells.
24 (el Mouzan et al. 1988) 13 F 6.5 10 1.3 0.2 1 1/640 + rhumatoid factor + + Decreased bone marrow activity with 1:1 myeloid
to erythroid ratio, megakaryocytes quantitatively
normal, increased reticulo-endothelial activity
and fibrosis.
25 (Kaelin and Spivak 1986) 27 F 13.1 5 4.4 2.8 0.9 1/1280 + antiplatelet,
anti-neutrophil
+ + Contained all normal hematopoietic elements
with a slight increase in mature megakaryocytes,
markedly increased reticulin.
26 (Nanji and Jetha 1984) 28 M 8.4 1 0.3 high - Hypocellular in some areas and hypercellular in
others, megakaryocytes decreased in number,
increased numbers of histiocytes and fibroblasts,
extensive fibrosis and diffuse increased in reticulin.
27 (Daly and Scott 1983) 16 F 7 28 1.7 0.5 1/1280 + - + Marked marrow fibrosis with reduced numbers of
erythroid precursors, plentiful megakaryocytes,
greatly increased reticulin content.
Present 29 F 2.9 15 0.48 0.28 0.08 1/1280 + anti-SSA, RNP 70,
U1-RNP
- + Hypercellular marrow (cellularity : 80%) with focal
lymphocytic infiltration, dysmyelopoiesis,
erythrophagocytosis and grade 1–2 fibrosis.
Hb: hemoglobin, Pl: platelets, WBC: white blood count, N: neutrophils, L: lymphocytes, ANA: anti-nuclear antibodies, DNA: anti double-stranded DNA antibodies, Co test: Coombs test, LC: low complement,
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109/l) was observed in 10/12 (16 missing data) patients,
lymphopenia in 4/9 (19 missing data), hemolysis with
hyper-reticulocytosis in one case and a positive direct
Coombs’ test in 10/18 (10 missing data). Hemoglobin
levels ranged from 13.1 to 2.7 g/dl (mean 7.3 g/dl), plate-
lets from 341 to 1 × 109/l (mean 50 × 109/l), and leuco-
cytes from 6.8 to 0.35 × 109/l (mean 3.4 × 109/l). Of the 24
patients with thrombocytopenia, 11 had deep (<20 × 109/l),
8 severe (<50 × 109/l), and 5 moderate thrombocytopenia.
Tear drop cells or leukoerythroblastic blood smear, two
common finding in primary myelofibrosis, were noted in
14 patients.
Bone marrow abnormalities (Table 2)
For 22/28 patients, a “dry tap” occurred during bone
marrow aspiration. All bone marrow biopsies showed
bone marrow fibrosis with variable increases in the
amount of reticulin fibers and fibroblasts. Grades of
bone marrow fibrosis were not always specified. Global
marrow cellularity was variable, ranging from increased
(12/28) to normal (11/28) or decreased (5/28) without
any increase in blasts. All elements including megakar-
yocytes appeared morphologically normal. Megakaryo-
cytes were increased or/and with clustering in 13/28
patients and decreased in 1/28. Focal or massive lympho-
cytic infiltration was observed in 4/28, plasmocytosis in
1/28 and erythroid hyperplasia in 2/28. Fifteen patients
underwent repeated bone marrow examination show-
ing improvement, with reduction in reticulin amounts
in 12/15.
Immunological abnormalities (Table 2)
Antinuclear antibodies were found in all patients, anti-
dsDNA in 12/28, anti-Ro/SSA in 2/28, anti-histone in 1/28,
and a low complement level in 18/28 patients. Antipho-
spholipid antibodies were detected in 4/28 patients. Anti-
platelet antibodies testing came out positive in 3 patients
and negative in 4.
Outcome and treatment (Table 3)
Follow-up time ranged from a few months to years
but was often unspecified. The overall mortality was
14% (4/28). Two patients died within few days with no
other treatment than blood transfusions and antibiotics.
Two other patients who died received only prednisone
as a specific treatment. Improvement was noted in 17/
28 patients, transient response with need for new treat-
ment in 5/28, and no improvement in 2/28. Supportive
care with antibiotics and transfusions was explicitly
mentioned for 8 patients. Two patients received gran-
ulocyte colony stimulating factor (G-CSF).
Immunomodulatory therapies consisted in corticosteroids
(26/28) (prednisone, prednisolone or methylprednisolone),intravenous immune globulins (4/28) (Ramakrishna et al.
1995; Aharon et al. 1997; Sacre et al. 2009), plasma ex-
changes (2/28) (Borba et al. 1993; Vora et al. 1998), azathio-
prine (2/28) (Foley-Nolan et al. 1992; Kiss et al. 2000),
cyclophosphamide (1/28) (Borba et al. 1993), cyclosporine
(1/28) (Kiss et al. 2000), danazol (1/28) (Ramakrishna et al.
1995), colchicine (1/28) (Ramakrishna et al. 1995), vin-
cristine (1/28) (Ramakrishna et al. 1995) and splenec-
tomy (1/28) (Ramakrishna et al. 1995). Of 20 patients
who received only corticosteroids, 16 improved and 4
did not. Four patients who received cortisone concomi-
tantly with azathioprine, intravenous immunoglobulin or
cyclosporine improved. One patient received cortisone and
showed a transient response but pancytopenia relapsed so
she received danazol, vincristine, colchicine, intravenous
immunoglobulins, then underwent splenectomy and finally
improved (Ramakrishna et al. 1995). Another patient was
treated with plasma exchanges and cyclophosphamide fol-
lowing a transient response to cortisone and improved
(Borba et al. 1993). One patient received intravenous
immune globulins after 3 weeks of corticosteroid treatment
without response, and a marked improvement occurred
within the following week (Aharon et al. 1997).
Discussion
Nosology
Primary myelofibrosis is considered as a clonal myelo-
proliferative disorder (Tefferi et al. 2012). However some
diseases such as infections, neoplasms and autoimmune
diseases may also induce bone marrow fibrosis. The
term “myelofibrosis” is used in some contexts to de-
scribe any increase in bone marrow stromal fibres, re-
gardless of the associated disease, and in other contexts
to define a specific myeloid disorder (primary myelofi-
brosis) (Kuter et al. 2007). The word “myelofibrosis” is
therefore ambiguous, and in this article we have chosen
rather to use the term “bone marrow fibrosis”. Some au-
thors suggest the importance of distinguishing between
increases in bone marrow reticulin and collagen. Above-
normal reticulin amounts are generally regarded as a
nonspecific sign of bone marrow abnormality, but may
or may not be a sign of serious neoplastic disease. In
contrast, increased collagen is less common and is
mainly seen in tumours metastatic to the bone marrow
or in the late stages of myeloproliferative diseases. Un-
like increased reticulin, it is not always reversible (Kuter
et al. 2007). In most cases reported here, it was unclear
if trichrome collagen stain and/or reticulin stain were
performed, and the type and amount of fibrosis were not
reported according to established grading scales (Kuter
et al. 2007). Another issue is whether finding bone mar-
row reticulin fibrosis per se should prompt a diagnosis
of autoimmune myelofibrosis in a patient with SLE. For
example, mild degrees of reticulin fibrosis can be
Table 3 Treatment
Nref Age (yrs) Sex (M/F) Medication received before
bone marrow fibrosis
Immunomodulatory therapy
for bone marrow fibrosis
Response
1 (Sarkar et al. 2009) 45 M Prednisolone 60 mg/d Improved
2 (Sacre et al. 2009) 44 F Prednisone, hydroxychloroquine Prednisone 1 mg/kg/d, IVIg Improved
3 (Pillai et al. 2009) 40 F IV methylprednisolone 500 mg/d,
prednisone
Improved
4 (Aziz et al. 2004) 22 F Prednisone 1 mg/kg/d Improved
5 (Kiss et al. 2000) 18 F Prednisone, azathioprine
discontinued 6 months prior
IV methylprednisolone 1 g/d ×3,




6 (Durupt et al. 2000) 29 F Prednisone 2 mg/kg/d Improved
7 (Vora et al. 1998) 22 F Prednisone, azathioprine initiated
2 weeks prior




8 (Aharon et al. 1997; Amital
et al. 2003)
54 F Prednisone 80 mg/d, IVIg
400 mg/kg/d ×5
Improved
9 (Agarwal et al. 1995) 12 F Prednisone 2 mg/kg/d Improved




11 (Paquette et al. 1994) 68 M Prednisone 20 mg/d Not improved
12 (Paquette et al. 1994) 27 F Prednisone 60 mg/d Improved
13 (Paquette et al. 1994) 23 F Prednisone 50 mg/d Improved
14 (Paquette et al. 1994) 56 F Prednisone Prednisone Not improved
15 (Paquette et al. 1994) 18 F Prednisone 80 mg/d Improved
16 (Paquette et al. 1994) 70 F Prednisone Deceased
17 (Paquette et al. 1994) 62 F Deceased
18 (Paquette et al. 1994) 69 F Prednisone, splenectomy Relapsed, secondary
improvement
19 (Hirose et al. 1993) 54 F IV methylprednisolone 1 g/d ×3,
prednisone 60 mg/d
Improved








22 (Inoue et al. 1992) 24 F Prednisolone 1,2 mg/kg/d,
IV methylprednisolone 1 g/d ×3
Improved
23 (Matsouka et al. 1989) 60 F Hydrocortisone 1 g/d Deceased
24 (el Mouzan et al. 1988) 13 F Prednisolone 30 mg/d Improved
25 (Kaelin and Spivak 1986) 27 F Prednisone, salicyclate IV methylprednisolone 100 mg/d ×6,
prednisone 50 mg/d
Improved
26 (Nanji and Jetha 1984) 28 M Prednisone Deceased
27 (Daly and Scott 1983) 16 F NSAID including
oxyphenbutazone
Prednisolone 30 mg/d Improved
Present 29 F Olanzapine IV methylprednisolone 500 mg/d ×3,
prednisone 1 mg/kg and
hydroxychloroquine, IVIg 30 g/d ×4
Improved
NSAID: non-steroidal anti-inflammatory drugs. IVIg: intravenous immunoglobulins.
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and may be found in many patients with lupus when rou-
tine bone marrow biopsies are performed (Pereira et al.
1998). Moreover, some authors have reported cases ofbone marrow fibrosis in patients who do not have SLE or
other well-defined autoimmune syndromes (Bass et al.
2001; Pullarkat et al. 2003). They have defined “primary
autoimmune myelofibrosis” as a disorder characterized by
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grade 3 - 4 reticulin fibrosis of the bone marrow, lack of
atypical bone marrow cells or osteosclerosis, absent or mild
splenomegaly, and the presence of auto-antibodies. In our
review, the 28 retrieved cases have been considered as ful-
filling criteria for SLE, although lupus symptoms and signs
leading to the diagnosis of SLE were not always reported in
detail by the authors. Their clinico-pathological features
were very similar to those of the reported cases of “primary
autoimmune myelofibrosis”. Thus we tend to believe that
“autoimmune myelofibrosis”, just like autoimmune cytope-
nias, may occur as an isolated disorder, or as a feature of
other autoimmune diseases including SLE. Finally, cases of
aplastic anemia have also been reported in SLE patients.
We found 25 published cases in the English language lit-
erature (Aplastic anemia as a feature of systemic lupus ery-
thematosus. In preparation). In these cases, the bone
marrow biopsy showed marked hypocellularity, but the ab-
sence of reticulin fibrosis was often not specified, and thus
the differentiation between “lupus bone marrow fibrosis”
and “lupus aplastic anemia” is not always clear, raising the
question of the borderland between these two rare features
of SLE (Cavalcant et al. 1978).
Pathophysiology
The pathogenesis of bone marrow fibrosis remains in-
completely understood, but appears to be a relatively
nonspecific response of fibroblasts to underlying cellular
abnormalities. Increased reticulin is the result of fibro-
blast proliferation, and increased collagen synthesis or
altered collagen turnover appear to be due to decreased
collagenase release from macrophages and neutrophils
(Kuter et al. 2007). Several growth factors appear to be
implicated. The platelet-derived growth factor (PDGF),
found in megakaryocytes and platelets, stimulates fibro-
blast growth (Kuter et al. 2007). The transforming growth
factor β (TGFβ) and epidermal growth factor (EGF) are
known to promote collagen synthesis (Le Bousse-Kerdilès
et al. 2008). Immunological abnormalities may be involved
in the pathogenesis. The increased circulating immune
complexes and auto-antibodies that are present in SLE
may act on megakaryocyte Fc receptors and release
growth factors to promote marrow fibrosis. Some authors
have suggested that both auto-antibodies against CD34+
stem cells and cytotoxic T cells may initiate and perpetu-
ate damage to the bone marrow (Kiss et al. 2000). An in-
crease in leucocyte apoptosis and impaired clearance of
apoptotic cells has also been observed in patients with
SLE. These apoptotic bodies were observed in the bone
marrow of patients with SLE, while they are not typically
seen in normal bone marrow. Delayed apoptotic cell clear-
ance leads to prolonged exposure of auto-antigens and
predisposes to antibody production (Hepburn et al. 2007).
Furthermore, in the bone marrow of patients with bonemarrow fibrosis and SLE, megakaryocyte counts are often
above normal or normal. Therefore thrombocytopenia
may result at least partly from an increased destruction of
the platelets rather than a decreased production caused by
bone marrow fibrosis. An association between immune
thrombocytopenia (to which bone marrow dysfunction is
increasingly believed to contribute (Gernsheimer 2009))
and bone marrow fibrosis has been observed in 3 of the
28 reported cases.
The JAK2 V617F mutation, associated with primary mye-
loproliferative disorders, is present in up to one half of the
patients with primary myelofibrosis (Tefferi et al. 2012).
Some authors suggest a thorough search for auto-immunity
in the absence of the mutation (Sacre et al. 2009).
Clinical and biological presentation
Primary myelofibrosis is diagnosed relatively late in life
(median age is 66 years) and is more common in males
(ratio 3:2) (Tefferi et al. 2012). Bone marrow fibrosis oc-
curring with SLE is diagnosed earlier (median age is
29 years) and is very uncommon in males (ratio 1:9). In
15/28 cases, the diagnosis of SLE and bone marrow fi-
brosis were made simultaneously. However, in 5 of these
cases a number of symptoms and signs (such as arthral-
gias, alopecia, proteinuria) were suggestive of undiagnosed
yet pre-existing SLE (Daly and Scott 1983; Matsouka et al.
1989; Inoue et al. 1992; Paquette et al. 1994; Pillai et al.
2009). Some authors suggest that autoimmune disorders,
including SLE, may be considered in cases of bone mar-
row fibrosis in patients whose spleen is not enlarged
(Pullarkat et al. 2003; Sacre et al. 2009), but 10/26 pa-
tients in our review had splenomegaly. Moreover, in
primary myelofibrosis, the clinical finding of splenomeg-
aly is associated with collagen, but not reticulin fibrosis
(Thiele and Kvasnicka 2006). Fifteen patients underwent
repeated bone marrow examinations showing improve-
ment, with a reduction in reticulin in 12/15. This suggests
that reticulin fibrosis (and maybe even collagen fibro-
sis) can be reversed if the underlying disease is treated
(Pereira et al. 1998).
Outcome and treatment
Although it is likely that negative outcomes are less fre-
quently reported in case reports, for which follow up
data may be lacking, and that consequently the overall
mortality may be higher than the 14% documented from
this review, this mortality rate suggests a more favourable
course for SLE-associated bone marrow fibrosis than for
primary myelofibrosis (Tefferi et al. 2012). Interestingly,
bone marrow fibrosis occurring with SLE appears to
often respond to corticosteroids, unlike primary mye-
lofibrosis. Plasma exchanges seem to have no efficacy.
Intravenous immune globulins were used for 4 patients
only (Ramakrishna et al. 1995; Aharon et al. 1997;
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least one patient (Aharon et al. 1997), as it was the case for
the patient we managed. None of the 28 patients received
rituximab. None received an allogeneic hematopoietic stem
cell transplant.
Conclusion
SLE may be complicated by bone marrow fibrosis, which
is likely to be of autoimmune origin. This feature may
be more common than previously thought, with cases
being incorrectly characterized as blood peripheral cyto-
penias in patients previously diagnosed with SLE, and
cases being misdiagnosed with primary myelofibrosis in
patients not previously diagnosed with SLE. We think
that in patients with SLE, cytopenias should be con-
firmed by bone marrow aspiration, and by bone marrow
biopsy in atypical or refractory cases. Moreover, auto-
immune myelofibrosis or SLE-associated bone marrow
fibrosis should be considered in cases of primary myelo-
fibrosis with atypical features such as young age and fe-
male sex, absence of spleen enlargement, or absence of
JAK2 V617F mutation, because this condition seems
amenable to efficient treatment. High-dose corticoster-
oid therapy with or without intravenous immune globu-
lins should be the first-line therapy.
In order to improve knowledge of bone marrow in-
volvement in SLE, we have established a French registry,
with centralized proofreading of bone marrow aspira-
tions and biopsies. We hope to achieve a sufficient sam-
ple size for epidemiological and clinical research on this
unusual feature of lupus.
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